Verily, Alphabet Inc.'s research organization devoted to the study of life sciences, acquired a stake in DexCom, a leader in continuous glucose monitoring, for $550m. “Our collaboration remains on track to deliver our next generation CGM platform by the end of 2020,” said Kevin Sayer, Chairman, President and Chief Executive Officer of Dexcom. “This agreement aligns Dexcom’s and Verily’s mutual interests in bringing Dexcom CGM technology to a broader diabetes population.”